Featured Suppliers:

Ads by Google


 

Insmed Incorporated


News and Blogs

Total : 3 View more »

Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2009

www.prnewswire.com

Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2009.

http://www.prnewswire.com/news-releases/insmed-announces-financial-results-for-third-quarter-and-nine-months-ended-september-30-2009-69362217.html

Insmed Is Well Positioned to Make a Good Deal -- Seeking Alpha

seekingalpha.com | Sep 28, 2009

When you look hard enough and turn over enough stones, you are bound to find something sooner or later. One company I found and purchased recently is Insmed, Inc. (INSM).

http://seekingalpha.com/article/163714-insmed-is-well-positioned-to-make-a-good-deal?source=feed

Insmed Receives NASDAQ Deficiency Notice Relating to Minimum Bid Price

news.prnewswire.com

RICHMOND, Va., Sept. 16 /PRNewswire-FirstCall/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that on September 15, 2009 it received a NASDAQ Staff Deficiency Letter from The NASDAQ Stock Market.

http://news.prnewswire.com/ViewContent.aspx?ACCT=109&STORY=/www/story/09-16-2009/0005095523&EDATE=

News from Zibb.com

Total : 36 View more »

 

Insmed Down 27.8% Since SmarTrend's Sell Recommendation - Zibb.com

Nov 23, 2009 (SmarTrend(R) Spotlight via COMTEX) --

SmarTrend, our proprietary pattern recognition system, called a Downtrend for Insmed (NASDAQ:INSM) on June 25, 2009 at $1.08.

Since then, Insmed has returned 27.8% as of today's recent price of $0.78. Want to profit from these alerts?

Go to www.mysmartrend.com now for a FREE two-week trial.

Write to Chip Brian at cbrian@tradethetrend.com

---------------------------------------------------------------------------------------------

SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.

Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup.html

Read more...

Tags: market   nasdaq   profit   securities   trial  

Companies: Insmed, Inc. (INSM)

Permalink

 

Insmed Down 25% Since SmarTrend's Sell Recommendation - Zibb.com

Nov 17, 2009 (SmarTrend(R) Spotlight via COMTEX) --

SmarTrend, our proprietary pattern recognition system, called a Downtrend for Insmed (NASDAQ:INSM) on June 25, 2009 at $1.08.

Since then, Insmed has returned 25% as of today's recent price of $0.81. Want to profit from these alerts?

Go to www.mysmartrend.com now for a FREE two-week trial.

Write to Chip Brian at cbrian@tradethetrend.com

---------------------------------------------------------------------------------------------

SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.

Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup.html

Read more...

Tags: market   nasdaq   profit   securities   trial  

Companies: Insmed, Inc. (INSM)

Permalink

 

Insmed Inc. (INSM) Corporate Event Announcement Notice - Zibb.com

Nov 06, 2009 (Wall Street Horizon via COMTEX) -- 

Insmed Inc. (INSM)

Expected next earnings release:
Announcement date: 11/6/2009 - Before Market
Earnings Quarter: Q3
Announcement Status: Verified

Expected next investor conference call information:
Conference Call Date: 11/6/2009
Conference Call Time (ET): 8:30 AM
Conference Call URL: http://phx.corporate-ir.net/playerlink.zhtml?c=122332&s=wm&e=2498647

Read more...

Tags: conference   corporate   earnings   market  

Companies: Insmed, Inc. (INSM)

Permalink

 

Insmed Down 25.7% Since SmarTrend's Sell Recommendation - Zibb.com

Nov 10, 2009 (SmarTrend(R) Spotlight via COMTEX) --

SmarTrend, our proprietary pattern recognition system, called a Downtrend for Insmed (NASDAQ:INSM) on June 25, 2009 at $1.08.

Since then, Insmed has returned 25.7% as of today's recent price of $0.80. Want to profit from these alerts?

Go to www.mysmartrend.com now for a FREE two-week trial.

Write to Chip Brian at cbrian@tradethetrend.com

---------------------------------------------------------------------------------------------

SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.

Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup.html

Read more...

Tags: market   nasdaq   profit   securities   trial  

Companies: Insmed, Inc. (INSM)

Permalink

 

Web Sites

Total : 74 View more »

Insmed Provides Update on Supply of IPLEX(TM)

www.bio-medicine.org

Health,... ... ...RICHMOND Va. July 27 /- Insmed Inc. (Nasdaq: ... ...,Insmed,Provides,Update,on,Supply,of,IPLEX(TM),medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news

http://www.bio-medicine.org/medicine-news-1/Insmed-Provides-Update-on-Supply-of-IPLEX-28TM-29-52763-1/

Tercica — Prospective Partnerships

Our primary goal in these partnerships is to provide our development commercialization expertise to companies whose products offer therapeutic benefits to patients with endocrine, metabolic, or related orphan diseases.

http://www.tercica.com/content.php?content_id=58

Copyright © 2009 MarketWatch, Inc. All rights reserved. Please see our Terms of Use. MarketWatch,...

Copyright © 2009 MarketWatch, Inc. All rights reserved. Please see our Terms of Use. MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc. Intraday data provided by Interactive Data Real-Time Services and subject to the Terms of Use.

http://www.holdrs.com/holdrs/main/index.asp?Action=Headlines&Description=&Image=&symb=INSM&sid=205428

DFB Pharmaceuticals, Inc.: Phyton Biotech Signs Development Agreement with Insmed

IPLEX was approved by the FDA in December 2005 for the treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH.

http://www.dfb.com/index.php?id=23&tx_ttnews[pS]=1203199508&tx_ttnews[pointer]=1&tx_ttnews[tt_news]=33&tx_ttnews[backPid]=61&cHash=baacb9735d

Web Sites powered by Bing

Total : 9,230 View more »

Insmed

www.insmed.com

Protein manufacturing facility concentrated on developing treatments for metabolic and endocrine disorders. Details of investor relations and cGMP process manufacturing at Boulder ...

http://www.insmed.com/

Insmed Incorporated (INSM) Company Profile - CorporateInformation.com ...

www.corporateinformation.com

Insmed Incorporated. The Group's principal activities are developing and marketing pharmaceutical products for the treatment of metabolic, hormone growth disorders, diabetes and ...

http://www.corporateinformation.com/Company-Snapshot.aspx?cusip=457669208

INSM: Summary for Insmed, Inc.- Yahoo! Finance

finance.yahoo.com

Insmed Incorporated Earnings Call scheduled for 8:30 am ET today CCBN (Fri, Nov 6) Specialty Pharma Stock Picks From David Amsellem Of Piper Jaffray Wall Street Transcript (Fri, Nov 6

http://finance.yahoo.com/q?s=insm

Insmed Incorporated - Overview

investor.insmed.com

We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Insmed Incorporated's ...

http://investor.insmed.com/